Despite the excellent finding of tyrosine kinase-targeted therapy for cancer treatment, such as imatinib for CML with BCR/ABL [21] or erlotinib for non-small-cell lung carcinoma [22], the resistance to the treatment still remains a difficult problem and there is a need to overcome it to get better healthcare. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.